Market closed · Next open: Monday 9:30 AM ET
Last update: Oct 9, 2026, 6:18 PM ET

Stock Analysis

Why did Danaher (DHR) stock fall ~13% on July 21, 2026 — a beat-and-raise undone by a core revenue guidance cut

Danaher fell nearly 13% on July 21, 2026 despite beating on adjusted EPS and raising its full-year earnings guidance. The company tied that raise partly to completing the Masimo acquisition early — while cutting full-year core revenue growth guidance to 3–4% from 3–6% and marking bioprocessing down to mid-single-digit growth. The market paid for the organic line, not the inorganic one. Bioprocessing peers Repligen and Sartorius fell in sympathy while instrument makers rose, on a day the broad market was up ~1%.

By BestStocks ResearchPublished (ET)13 min readDHR
Bioprocessing single-use bioreactor equipment in a life-sciences manufacturing facility, illustrating Danaher's Q2 2026 core revenue guidance cut that drove the stock down about 13% on July 21, 2026

Summary

Danaher (NYSE: DHR) was trading at $175.20 at about 1:07 p.m. ET on Tuesday, July 21, 2026, down $25.91, or 12.88%, from Monday's $201.11 close [1][2]. This article was written intraday; the figures below are timestamped and are not closing prices.

The puzzle is that this was, on its headline numbers, a beat and a raise. Danaher reported second-quarter adjusted earnings of $1.94 a share against roughly $1.83–$1.84 expected, grew revenue 5.5% to $6.27 billion, and raised its full-year adjusted EPS guidance to $8.45–$8.60 from $8.35–$8.55 [3][4]. Companies that beat and raise do not usually fall 13%.

The answer is in the composition. Danaher's own release attributes the EPS increase to "strong Q2 earnings performance and earlier-than-anticipated completion of [the] Masimo acquisition" — that is, partly inorganic [3]. The organic measure moved the other way: full-year core revenue growth guidance was cut to 3.0%–4.0% from 3.0%–6.0%, with the bioprocessing growth outlook taken from high-single-digit to mid-single-digit [3][5]. The market separated the two and priced the organic line.

Evidence levelWhat can be said
DocumentedDHR traded −12.88% at $175.20 at ~1:07 p.m. ET on volume 3.29× its 20-day average with the session ~56% elapsed; Q2 adjusted EPS of $1.94 beat and revenue rose 5.5%; full-year core revenue guidance was cut to 3.0%–4.0% from 3.0%–6.0% while adjusted EPS guidance was raised to $8.45–$8.60; Q3 core guidance of 2.0%–3.0% is below the new full-year range; bioprocessing peers fell hard while non-bioprocessing tools names rose [1][2][3].
Reported interpretationThe selloff reflects the market discounting an EPS raise the company itself ties partly to pulling the Masimo acquisition forward, while marking down the organic growth rate — with bioprocessing, the segment that drove Danaher's premium multiple, at the centre of the markdown [3][5].
Author inference / not measurableWhether bioprocessing's shortfall is genuinely "customer project timing," as management says, or the start of a demand problem cannot be settled from one quarter — orders grew mid-teens, which cuts against the bearish read. No sell-side note had been published at the time of writing, so no analyst reaction is reported here. The scenario values below are illustrative estimates, not forecasts.

What changed

MetricValueAs of / source
Price (intraday)$175.20Jul 21 2026, ~1:07 p.m. ET — StockAnalysis [2]
Prior close (Jul 20)$201.11StockAnalysis [2]
Change−$25.91 / −12.88%Vs prior close, ~1:07 p.m. ET [2]
Day's range$165.75 – $178.58Jul 21 2026, ~1:06 p.m. ET; the low sits ~3% above the 52-week low [2]
52-week range$160.93 – $242.80~28% below the high [2]
Volume~15.76M shVs a 4.79M 20-day average — 3.29× normal, with only ~56% of the session elapsed [2][6]
Market cap~$123.8bnStockAnalysis, Jul 21 [2]
Valuation23.25× forward / 38.98× trailingVs Thermo Fisher at 20.74× forward, same source and day [2][7]
Analyst consensus$242.52 (Buy, 26)StockAnalysis, Jul 21 1:07 p.m. — predates any post-Q2 revision [2]

Participation was heavy, and that matters here. Danaher traded about 15.8 million shares against a 4.79-million 20-day average — roughly 3.3× normal — with barely more than half the session gone [2][6]. On pace, the full day lands materially higher still. A double-digit decline on triple-average turnover in a $124 billion mega-cap reflects unusually heavy and broad repositioning, not a thin-tape drift. (Volume alone does not identify who traded — institutions, systematic funds, options hedging and retail all sit inside that print.) That distinguishes this from a move that can be dismissed as noise — though volume measures conviction, not correctness.

The catalyst: a beat and a raise that the market read as a downgrade

Taken line by line, Danaher's quarter was fine. Revenue of $6.27 billion rose 5.5% year over year; GAAP diluted EPS of $1.23 was up 60% from $0.77; adjusted diluted EPS of $1.94 rose 8.0% from $1.80 and came in above the roughly $1.83–$1.84 the Street wanted [3][4]. Core revenue grew 3.0%, or 4.5% excluding respiratory testing — a comparison distortion the company strips out because pandemic-era respiratory revenue is still rolling off [3].

The segment detail is where the softness shows. Against total sales growth, core growth was materially thinner in two of three segments:

SegmentTotal sales growthCore sales growthCore less total
Biotechnology+4.0%+2.5%−1.5pp
Life Sciences+5.5%+5.5%—
Diagnostics+7.0%+2.0%−5.0pp

Life Sciences — which CEO Rainer M. Blair said "delivered their strongest quarter in several years" — was the one segment where every dollar of growth was organic [3]. Biotechnology, which houses bioprocessing and is the franchise the market pays Danaher's premium multiple for, grew core sales just 2.5% [3].

Diagnostics needs a caveat, because the raw gap overstates the weakness. Its 7.0% total growth against 2.0% core is not five points of evaporating demand — the segment's reported growth came primarily from the Masimo acquisition, with acquisitions adding 1.5% and currency 1.0% to group reported sales [16]. And the 2.0% core figure is itself depressed by the respiratory-testing roll-off that Danaher now strips out explicitly: excluding respiratory testing, core sales grew 5.0% [3][16]. So the honest read of Diagnostics is mid-single-digit underlying growth flattered at the reported line by M&A and dragged at the core line by a known, disclosed comparison distortion — not a demand problem. The segment that actually drove the selloff is Biotechnology, where the 2.5% core figure has no such offsetting explanation.

Then came the guidance, and this is the crux:

Full-year 2026 guidancePreviousNowDirection
Core revenue growth3.0% – 6.0%3.0% – 4.0%Cut — top end −200bps
Adjusted diluted EPS$8.35 – $8.55$8.45 – $8.60Raised — +$0.10 / +$0.05
Q3 2026 core revenue growth—2.0% – 3.0%Below the new full-year range

Note the asymmetry. The EPS raise is a dime at the bottom and a nickel at the top. The core revenue cut removed two-thirds of the guided range — the floor held at 3.0% while the ceiling fell from 6.0% to 4.0%, taking the band from 300 basis points wide to 100 [3][8]. A company guiding to 3–6% is telling you a 6% outcome is live; one guiding to 3–4% has taken that outcome off the table. And the Q3 guide of 2.0%–3.0% sits below even the reduced full-year range, which implies the reacceleration is back-half-weighted — a promise rather than a result [3].

A bioprocessing read-across, not a sector selloff

The same-day tape is unusually informative, because it makes the two easy explanations very hard to sustain. This was not a down market and it was not a health-care selloff. The S&P 500 ETF was up 0.90%, the Nasdaq-100 ETF up 1.95%, and biotech (XBI) up 2.27% [10]. The health-care sector ETF XLV was fractionally green at +0.08% — despite Danaher being 2.20% of it, a weight at which a −12.88% move alone subtracts about 0.28 percentage points from the index [10][11]. The rest of health care more than absorbed it.

But it was not purely idiosyncratic either. The damage was concentrated in bioprocessing exposure, and it split the tools complex cleanly in two:

CompanyMove (Jul 21)PriceBioprocessing exposure
Danaher (DHR)−12.88%$175.20Core franchise
Sartorius (SRT3, Xetra pref.)−8.51%€217.20Pure-play
Repligen (RGEN)−7.67%$134.34Pure-play
Thermo Fisher (TMO)−1.69%$517.34Diversified
Bio-Rad (BIO)−0.89%$299.21Limited
Agilent (A)+1.49%$132.20Minimal
Waters (WAT)+1.71%$363.64Minimal
Revvity (RVTY)+3.19%$109.84Minimal

The gradient is almost perfectly ordered by bioprocessing exposure. The two pure-plays — Repligen and Sartorius — fell 7.7% and 8.5%. The diversified names barely moved. The analytical-instrument names, which sell into different end markets entirely, rose on a strong tape [12][13][14]. The pattern is consistent with a market repricing bioprocessing-specific growth expectations rather than the life-science tools group as a whole — though a day's relative moves show the shape of the repricing, not the reasoning behind it.

Bar chart of July 21 2026 intraday moves: Danaher -12.88%, Sartorius -8.51%, Repligen -7.67%, Thermo Fisher -1.69%, Bio-Rad -0.89%, Agilent +1.49%, Waters +1.71%, Revvity +3.19%, with SPY +0.90% and XLV +0.08% for context
The selloff tracked bioprocessing exposure, not the sector: pure-plays fell 8–9%, diversified peers barely moved, and instrument names rose on a market that was up ~1%. Sources: StockAnalysis, July 21 2026, ~12:52–1:08 p.m. ET [2][10][12].

Danaher still fell roughly four to five percentage points more than the worst pure-play. That excess is the company-specific component — the guidance cut, the Q3 number below the full-year range, and the questions about an EPS raise leaning on acquisition timing. In other words, the move decomposes into a sector-adjacent read-across plus a Danaher-specific markdown, and the second piece is the larger one.

What the sell-side had not yet said

One thing this article deliberately does not contain is a list of post-earnings analyst reactions, because at the time of writing there were none. Danaher reported before the open; sell-side notes on a pre-market print conventionally publish the following morning. As of the 1:07 p.m. ET timestamp, the dated rating trackers cited here showed the most recent DHR analyst action as July 6, 2026 — Evercore ISI's Vijay Kumar trimming his target to $230 from $232 while maintaining Outperform, two weeks before the quarter [9][15].

This matters for how the widely-quoted consensus should be read. The $242.52 average target across 26 analysts [2] reflects a pre-print world in which core revenue could still grow 6%. Quoting it against a $175.20 price to imply ~38% upside would be a category error — the number has not been updated for the information that caused the drop. The honest statement is that the pre-earnings target cluster sat around $200–$270 (Piper Sandler $200 Neutral, DZ Bank $210, Barclays / Citi / HSBC / Evercore around $230, BofA $270) and that these will be revised [9][15].

Verification also turned up several stale items being circulated as current — a Rothschild & Co Redburn downgrade actually dated October 2025, an HSBC target cut from June 3, and an unverifiable claim of July target raises that contradicts Piper Sandler's actual Neutral rating. None are used here. Readers checking this story elsewhere in the next few days should check dates carefully.

What this means for value

Danaher is a serial acquirer with a high-quality installed base, so its multiple is a function of the organic growth rate the market believes in. The scenarios below are the author's own illustrative estimates, anchored to the new adjusted EPS guidance midpoint (~$8.53), to Thermo Fisher's 20.74× forward multiple as a comparable, and to the pre-print analyst target distribution — not the output of a model. They sum to 100%.

Horizontal bar chart of Danaher price levels: 52-week high $242.80, stale consensus target $242.52, bull scenario $215, prior close $201.11, blended scenario value $184, base scenario $185, current price $175.20, bear scenario $150 and 52-week low $160.93
At $175.20 intraday, DHR sits ~5% below the author's ~$184 probability-weighted scenario value and ~14% above the bear case. The $242.52 consensus is shown for reference only — it predates the print. Sources: StockAnalysis; author's blend [2][9].
ScenarioPriceProbabilityKey driver
Bull~$21525%Management's "timing" explanation proves right — mid-teens bioprocessing order growth converts to revenue, core reaccelerates through the 4% ceiling in H2, and Masimo plus StatLab compound. A ~25× multiple on ~$8.53, recovering most of the gap toward the pre-print $230 target cluster [3][9]
Base~$18550%Core growth settles in the guided 3–4%, mid-single-digit bioprocessing is the new run-rate, and the forward multiple compresses toward the low-22× area — still a modest premium to Thermo Fisher's 20.74×, justified by the acquisition engine but no longer capitalising 6% organic growth [3][7]
Bear~$15025%"Customer project timing" turns out to mask genuine demand softness; Q3's 2–3% guide proves a trend rather than a trough, the back-half reacceleration does not arrive, and DHR de-rates below Thermo Fisher to ~17–18× — taking it through the $160.93 52-week low [2][3]
Probability-weighted scenario value ≈ $184 (inputs blend to $183.75, rounded; an illustrative estimate, not an objective fair value) — the $175.20 intraday price sits about 5% below it, implying roughly +5% of upside, with the $150 bear case ~14% lower.

The honest conclusion is that the selloff moved Danaher from expensive to approximately fair, not to cheap. A ~5% gap to a blended scenario value is inside the noise band of the assumptions behind it — meaningfully different from the ~19% discount Alcoa showed after its guidance cut. The asymmetry is not obviously attractive either: ~$40 of upside to the bull case against ~$25 of downside to the bear, with the bear scenario breaching the 52-week low. What resolves it is not the multiple but a single empirical question — whether mid-teens bioprocessing order growth shows up as revenue in the third and fourth quarters. Treat the ~$184 figure as an illustrative probability-weighted scenario value, not a target.

What to watch

  • Bioprocessing orders-to-revenue conversion — the decisive variable, but on a longer clock than it first appears. Management disclosed mid-teens order growth against soft revenue and said more than $100 million has moved principally from Q2 and Q3 into 2027 [3][17]. A weak Q3 is therefore consistent with the timing explanation as well as with a demand problem; what discriminates between them is whether the deferred revenue actually lands in 2027 and whether order growth holds in the meantime.
  • The Q3 print against 2.0%–3.0% core guidance — the full-year 3–4% range requires a back-half acceleration. A Q3 at or below the low end would make the 3% floor itself look optimistic [3].
  • The first wave of analyst revisions — none had published at the time of writing. Where the $242.52 consensus resets, and whether any firm cuts its rating rather than just its target, will be the clearest read on how the sell-side interprets the guidance cut [2][9].
  • The forward-multiple premium to Thermo Fisher — DHR still trades at 23.25× versus TMO's 20.74×. Whether that premium holds, widens or closes is the market's running verdict on Danaher's organic growth [2][7].
  • Bioprocessing peers as a cross-check — Repligen and Sartorius fell in sympathy without reporting. Their own prints will show whether Danaher's markdown was company-specific or an industry signal [12][13].
  • StatLab and Masimo integration — if the EPS raise is partly acquisition-driven, execution on those deals carries more weight than usual. StatLab is expected to close by the end of 2026 [3].

Frequently asked questions

Why did Danaher (DHR) stock fall on July 21, 2026?

Danaher fell about 12.9% to $175.20 intraday despite reporting a second-quarter beat. Adjusted EPS of $1.94 topped the roughly $1.83-$1.84 consensus and the company raised full-year adjusted EPS guidance to $8.45-$8.60 from $8.35-$8.55. But it cut full-year core revenue growth guidance to 3.0%-4.0% from 3.0%-6.0%, reduced its bioprocessing growth outlook from high-single-digit to mid-single-digit, and guided third-quarter core growth to just 2.0%-3.0% — below even the reduced full-year range. Danaher also attributed the EPS raise partly to completing the Masimo acquisition earlier than anticipated, meaning the earnings upside was partly inorganic while the organic growth outlook came down.

Did Danaher beat or miss earnings in Q2 2026?

It beat. Adjusted diluted EPS of $1.94 was up 8.0% from $1.80 a year earlier and came in above consensus estimates of roughly $1.83-$1.84. Revenue rose 5.5% to $6.27 billion and GAAP diluted EPS of $1.23 was up 60% from $0.77. The stock fell anyway because the market focused on the forward guidance rather than the reported quarter. The $1.23 figure that appears in some coverage is the GAAP number, not a miss against the adjusted estimate.

What exactly did Danaher change in its guidance?

Two things moved in opposite directions. Full-year 2026 core revenue growth guidance was cut to 3.0%-4.0% from the previous 3.0%-6.0% — the floor was unchanged but the ceiling came down 200 basis points, removing two-thirds of the guided range (the band narrowed from 300 basis points wide to 100). Full-year adjusted diluted EPS guidance was raised to $8.45-$8.60 from $8.35-$8.55, an increase of $0.10 at the bottom and $0.05 at the top. Danaher also guided third-quarter core revenue growth to 2.0%-3.0%, below the new full-year range, which implies any reacceleration is weighted to the fourth quarter.

What happened with Danaher's bioprocessing business?

Bioprocessing sits inside the Biotechnology segment, which grew total sales 4.0% but core sales just 2.5%. CEO Rainer M. Blair said that while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter. The company nonetheless reduced its bioprocessing growth outlook from high-single-digit to mid-single-digit. On the earnings call management quantified the displacement: more than $100 million of revenue has shifted, principally out of the second and third quarters and into 2027, and management said it considers it highly unlikely those pushouts do not return. That detail matters for how quickly the question can be settled — because the revenue was deferred into 2027 rather than merely delayed by weeks, a soft third quarter is consistent with both the timing explanation and a genuine demand problem. Whether the shortfall is timing or the beginning of a demand problem is the central unresolved question for the stock.

Was this a life-sciences sector selloff?

Not broadly — the weakness was concentrated in companies with direct bioprocessing exposure, and the same-day tape shows it. The broad market was up — the S&P 500 ETF gained 0.90%, the Nasdaq-100 ETF 1.95% and biotech (XBI) 2.27% — while the health-care sector ETF XLV was fractionally positive at +0.08%. The damage tracked bioprocessing exposure specifically: pure-plays Sartorius and Repligen fell 8.51% and 7.67%, diversified Thermo Fisher fell 1.69% and Bio-Rad 0.89%, while instrument makers with minimal bioprocessing exposure rose — Agilent +1.49%, Waters +1.71% and Revvity +3.19%. Danaher fell four to five points more than the worst pure-play, which is the company-specific component.

What did analysts say about Danaher after the Q2 report?

Nothing yet, as of the time of writing. Danaher reported before the market opened and sell-side reaction notes to a pre-market print conventionally publish the following morning. The most recent dated analyst action on DHR was July 6, 2026, when Evercore ISI's Vijay Kumar trimmed his target to $230 from $232 while maintaining Outperform — two weeks before the quarter. This is important context for the widely quoted $242.52 consensus price target across 26 analysts: it predates the print entirely and has not been revised for the guidance cut, so comparing it to the current price to infer upside would be misleading.

Is Danaher stock cheap after the July 2026 drop?

It looks approximately fair rather than cheap. Even after a 13% decline, DHR trades at 23.25 times forward earnings versus Thermo Fisher's 20.74 times, so the premium survived the selloff. On the author's illustrative probability-weighted scenario value (bull ~$215 at 25%, base ~$185 at 50%, bear ~$150 at 25%, blending to about $184), the $175.20 intraday price sits roughly 5% below that blend — a gap inside the noise band of the assumptions behind it. The bear case at ~$150 would take the stock through its $160.93 52-week low. What resolves the question is whether the mid-teens bioprocessing order growth converts into revenue in the second half. These figures are illustrative descriptive analysis, not investment advice.

View all research →
An abstract visualization of a sharply rising stock chart over restaurant and dining motifs with a question-mark overlay, in warm amber and green tones, representing Chipotle's surge on an unconfirmed Starbucks takeover report.
Stock AnalysisOctober 8, 2026 · 9 min read

Chipotle (CMG) Surges ~6% on a Report Starbucks Explored a Takeover

Chipotle jumped about 6% to roughly $32.54 on October 8 — after running as high as about $33.40 — on a Financial Times report that Starbucks has explored a potential takeover of the burrito chain. The key word is explored: the report describes preliminary, exploratory interest, not a formal offer, and neither company confirmed a deal, so this is a stock moving on takeover speculation that could reverse if the idea goes no further. The speculation still landed hard — volume ran about three times normal — because a Starbucks–Chipotle combination would be enormous (nearly $50 billion in combined sales, potentially the largest restaurant deal ever if completed) and would reunite Starbucks CEO Brian Niccol with the chain he ran from 2018 to 2024. It resonated partly because Chipotle had become cheap for Chipotle: down about 19% over the past year and trading below the ~$44 average analyst target even after the pop, a high-quality, cash-generative brand at a discount is exactly the profile that draws suitors. But skepticism is warranted: Starbucks fell about 3% on the prospect of a $45-billion-plus deal that would strain its balance sheet mid-turnaround, the strategic fit between coffee and fast-casual Mexican is debatable, and exploratory interest frequently never becomes an offer. The classic M&A-speculation cross-section — target up, acquirer down, McDonald's higher — tells the story; the next hard data is Chipotle's October 28 earnings.

An abstract visualization of a rising stock chart over data-storage and server-rack motifs with an upward target ladder, in blue and teal tones, representing NetApp's rise on an analyst upgrade in an AI-storage re-rating.
Stock AnalysisOctober 7, 2026 · 10 min read

NetApp (NTAP) Rises ~3.5% as Evercore Upgrades to a Street-High $300 on AI Storage

NetApp outperformed a weaker broader market on October 7, rising about 3.5% to roughly $236.50 after Evercore ISI's Amit Daryanani upgraded the stock from In Line to Outperform and set a Street-high $300 price target, up from $210. The move was less about one call than the cluster behind it: over roughly a week, Loop Capital went to $260, TD Cowen to $250, and Goldman to $240, and Evercore has now leapfrogged them all with a rating upgrade — a sell-side re-rating of NetApp as an AI-storage beneficiary, its all-flash arrays and ONTAP software positioned for the data pipelines that feed GPU clusters (a story reinforced by its late-September deal to buy PEAK:AIO and its Novus launch, both earlier developments rather than a fresh catalyst). NetApp rose even as long-dated Treasury yields hit their highest since 2002 in a rates- and oil-driven risk-off that pressured high-multiple shares. But the stock is not cheap: up roughly 96% over the past year, it trades near 23 times forward earnings and 6 times sales for a business growing revenue in the low-double-digits, so the upgrades are betting AI lifts both growth and the multiple. And the Street is genuinely split — the published average target near $206 sits below the price, reflecting both the lag before the newest hikes propagate and real disagreement: a camp of fresh below-price targets (Wedbush's Hold at $170, plus Citi, Barclays and Bank of America in the $190–$220 range) against the bulls at $240–$300. Without an unusually heavy-volume surge, this is a sell-side re-rating; the fundamentals arrive with December 1 earnings.

An abstract visualization of a sharply rising stock chart over vaccine-vial and molecular motifs in blue and teal tones, representing Vaxcyte's surge after its 31-valent pneumococcal vaccine cleared a pivotal Phase 3 trial.
Stock AnalysisOctober 5, 2026 · 9 min read

Vaxcyte (PCVX) Surges ~35% as VAX-31 Meets All Primary Endpoints in Pivotal Phase 3 Trial

Vaxcyte surged to roughly $76 on October 5 — up about 35% after opening near $87 (about +54%) — when it reported positive topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine. The trial met all of its prespecified primary endpoints on immune-response and safety measures: in adults 50 and older, VAX-31 met non-inferiority on all 20 serotypes it shares with Pfizer's Prevnar 20 and 17 of the 19 it shares with Merck's Capvaxive (the two exceptions cleared only a less-stringent historical bar), and superiority on the three serotypes unique to VAX-31, with safety similar to the incumbents. It is the profile a broader, 31-valent shot needs to take share in a multi-billion-dollar adult pneumococcal market — and the market priced it as a transfer of value, with Pfizer down about 1.6% and Merck about 3.4% while the biotech index was flat. Vaxcyte is still a clinical-stage, pre-revenue company — a roughly $1 billion annual loss, no P/E, and years from revenue, with two more Phase 3 trials due in 2027 and a planned filing in 2028 — but about $2.5 billion of cash and investments gives it runway, and sell-side targets sit well above the current price (Guggenheim raised its target to $125 the same day; Mizuho and Jefferies reiterated standing Buys at $163 and $146). The stock's gap-up-then-fade captures the tension between clearly good data and the execution still ahead.